Streetbeat News

FIXX

Homology Medicines Inc

https://www.homologymedicines.com/

CEO

Arthur Tzianabos

Employees

131

Industry

Pharmaceutical Preparation Manufacturing

homology medicines is a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases.

Open

0.92

Mkt cap

Volume

401K

High

0.97

P/E Ratio

-0.03

52-wk high

26.64

Low

0.90

Div yield

N/A

52-wk low

0.90

During Friday's intraday session, several health care stocks experienced significant movements. Gainers included Reata Pharmaceuticals (RETA), Homology Medicines (FIXX), Bluejay Diagnostics (BJDX), Gracell Biotechnologies (GRCL), Pulse Biosciences (PLSE), and Larimar Therapeutics (LRMR). Losers included Tonix Pharmaceuticals (TNXP), Mallinckrodt (MNK), Intelligent Bio Solutions (INBS), G Medical Innovations (GMVD), Femasys (FEMY), and Marker Therapeutics (MRKR).

Portfolio Pulse from Benzinga Insights

July 28, 2023 | 5:31 pm

The article lists the stocks that gained and lost the most during Friday's mid-day trading session. Among the gainers were Unique Fabricating, Reata Pharmaceuticals, and Bluejay Diagnostics, while the losers included Tonix Pharmaceuticals, Sleep Number Corporation, and Femasys Inc. Avantor shares fell by 9.9% due to worse-than-expected Q2 financial results.

Portfolio Pulse from Lisa Levin

July 28, 2023 | 5:07 pm

Homology Medicines is considering strategic options, which has led to an increase in the company's stock price.

Portfolio Pulse from Benzinga Newsdesk

July 28, 2023 | 3:51 pm

Homology Medicines Inc (NASDAQ:FIXX) announced initial data from its pheEDIT Phase 1 trial, showing positive results. However, due to the current financing environment and anticipated clinical development timelines, Homology will not be further developing its programs and will be reducing its workforce by 87%. The company has retained TD Cowen as its strategic financial advisor. These measures are expected to extend Homology's cash runway into 2026. As of March 31, 2023, Homology had approximately $150.0 million in cash, cash equivalents, and short-term investments. FIXX shares are up 23.40% at $1.16 during the premarket session on the last check Friday.

Portfolio Pulse from Vandana Singh

July 28, 2023 | 1:14 pm

Several healthcare stocks experienced significant movement in Friday's pre-market session. Gainers included Reata Pharmaceuticals, Bluejay Diagnostics, SIGA Technologies, Homology Medicines, Creative Medical Tech, and Asensus Surgical. Losers included Tonix Pharmaceuticals, Bellerophon Therapeutics, Femasys, Telesis Bio, Mallinckrodt, and Titan Pharma.

Portfolio Pulse from Benzinga Insights

July 28, 2023 | 1:06 pm

In the last quarter, Homology Medicines (NASDAQ:FIXX) received two bullish and two indifferent analyst ratings. Over the past three months, four analysts have offered 12-month price targets for the company, with an average price target of $7.62, representing a 10.35% decrease from the previous average price target of $8.50.

Portfolio Pulse from Benzinga Insights

July 28, 2023 | 12:01 pm

Several stocks are experiencing significant pre-market movements. Coursera shares are up by 15.3% following better-than-expected Q2 sales results and an upgrade from Cantor Fitzgerald. Other gainers include Unique Fabricating, Greenbrook TMS, SIGA Technologies, Homology Medicines, Inpixon, AEye, Navidea Biopharmaceuticals, Intel Corporation, and Asensus Surgical. Losers include Tonix Pharmaceuticals, Sleep Number Corporation, Bellerophon Therapeutics, Mallinckrodt, Fresh Vine Wine, Enphase Energy, Femasys, Sigma Additive Solutions, Sweetgreen, and Yoshiharu Global.

Portfolio Pulse from Lisa Levin

July 28, 2023 | 11:57 am

Baird analyst Madhu Kumar has downgraded Homology Medicines (NASDAQ:FIXX) from Outperform to Neutral and lowered the price target from $9 to $1.5.

Portfolio Pulse from richadhand@benzinga.com

July 28, 2023 | 9:33 am

Homology Medicines is planning to evaluate strategic options and has reduced its workforce by 87%. The company's drastic downsizing could be a sign of financial distress.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 9:33 pm

Several healthcare stocks experienced significant movement in Thursday's after-market session. Gainers included SIGA Technologies, Homology Medicines, INVO Bioscience, AIM ImmunoTech, electroCore, and vTv Therapeutics. Losers included Tonix Pharmaceuticals, Femasys, Mettler-Toledo Intl, Inozyme Pharma, MyMD Pharmaceuticals, and Reshape Lifesciences.

Portfolio Pulse from Benzinga Insights

July 27, 2023 | 9:32 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.